Comparison of Clinical Efficacy and Safety between Misoprostol and Oxytocin in the Prevention of Postpartum Hemorrhage: A Meta-Analysis
- PMID: 35449871
- PMCID: PMC9017444
- DOI: 10.1155/2022/3254586
Comparison of Clinical Efficacy and Safety between Misoprostol and Oxytocin in the Prevention of Postpartum Hemorrhage: A Meta-Analysis
Retraction in
-
Retracted: Comparison of Clinical Efficacy and Safety between Misoprostol and Oxytocin in the Prevention of Postpartum Hemorrhage: A Meta-Analysis.J Healthc Eng. 2023 Oct 4;2023:9895282. doi: 10.1155/2023/9895282. eCollection 2023. J Healthc Eng. 2023. PMID: 37829399 Free PMC article.
Abstract
In order to systematically evaluate the clinical efficacy and safety of misoprostol versus oxytocin in the prevention of postpartum hemorrhage, this paper provides evidence-based reference for clinical medication, computerized retrieval of Chinese biomedical literature database (CBM), PubMed, Embase, Cochrane Library, and clinical trials. The retrieval period is from the establishment of each database to October 1, 2021. Published randomized controlled trials (RCTS) are included in this study. The literature is screened and evaluated according to inclusion and exclusion criteria, and meta-analysis is performed using RevMan 5.3 software. A total of 13 RCTS are included, with a total of 24754 parturients. The meta-analysis shows the average blood loss (SMD = 0.10, 95% CI (-0.11, 0.32), P=0.35), the time of the third stage of labor (SMD = 0, 95% CI (-0.07, 0.08), P=0.95), and blood transfusion rate (RR = 0.80, 95% CI (0.63, 1.02), P=0.07). However, the incidences of shivering (RR = 2.61, 95% CI (1.79, 0.81), P < 0.00001) and vomiting (RR = 2.78, 95% CI (1.85, 4.18), P < 0.00001) are significantly higher than those in oxytocin group. The effect of misoprostol on preventing postpartum hemorrhage is similar to that of oxytocin, but the incidence of adverse reactions is high, and the occurrence of adverse reactions should be closely watched in the use process. Due to the limitations of the included studies, multicenter, large-sample, and high-quality RCTS are still needed in the future to further verify this conclusion.
Copyright © 2022 Renmei Xu et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Figures








Similar articles
-
Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in low-risk women.Int J Gynaecol Obstet. 2012 Feb;116(2):138-42. doi: 10.1016/j.ijgo.2011.09.016. Epub 2011 Nov 17. Int J Gynaecol Obstet. 2012. PMID: 22100204 Clinical Trial.
-
Active Management of the Third Stage of Labor With a Combination of Oxytocin and Misoprostol to Prevent Postpartum Hemorrhage: A Randomized Controlled Trial.Obstet Gynecol. 2016 Oct;128(4):805-11. doi: 10.1097/AOG.0000000000001626. Obstet Gynecol. 2016. PMID: 27607864 Clinical Trial.
-
Adjunctive rectal misoprostol versus oxytocin infusion for prevention of postpartum hemorrhage in women at risk: a randomized controlled trial.J Obstet Gynaecol Res. 2012 Nov;38(11):1294-301. doi: 10.1111/j.1447-0756.2012.01869.x. Epub 2012 May 21. J Obstet Gynaecol Res. 2012. PMID: 22612662 Clinical Trial.
-
Misoprostol use during the third stage of labor.Int J Gynaecol Obstet. 2003 Aug;82(2):143-52. doi: 10.1016/s0020-7292(03)00146-2. Int J Gynaecol Obstet. 2003. PMID: 12873774 Review.
-
Misoprostol for the prevention and treatment of postpartum haemorrhage.Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):1025-41. doi: 10.1016/j.bpobgyn.2008.08.005. Epub 2008 Sep 10. Best Pract Res Clin Obstet Gynaecol. 2008. PMID: 18786863 Review.
Cited by
-
Retracted: Comparison of Clinical Efficacy and Safety between Misoprostol and Oxytocin in the Prevention of Postpartum Hemorrhage: A Meta-Analysis.J Healthc Eng. 2023 Oct 4;2023:9895282. doi: 10.1155/2023/9895282. eCollection 2023. J Healthc Eng. 2023. PMID: 37829399 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources